Showing results (81-90 of 84) with videos related to
Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
The Lancet. Oncology|November 25, 2010
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityWyndham H Wilson, Owen A O'Connor, Myron S Czuczman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumorsLeena Gandhi, D Ross Camidge, Moacyr Ribeiro de Oliveira, et al.Pharmacogenetics and Genomics|May 15, 2013
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751Federico Innocenti, Jacqueline Ramírez, Jennifer Obel, et al.Cancer Research|August 29, 2025
MYADM Activates RhoA-Mediated Amoeboid Migration to Drive MetastasisYi-Ta Tsai, En-Ting Liu, Ming-Hsin Yang, et al.Pageof 9